Endoscopic Options for Gastroesophageal Reflux: Where Are We Now and What Does the Future Hold?

被引：8

作者：

Triadafilopoulos G. ^{[1
]}

机构：

[1] Division of Gastroenterology and Hepatology, Stanford University School of Medicine, 300 Pasteur Drive, M-211, Stanford, 94306, CA

来源：

Current Gastroenterology Reports | 2016年 / 18卷 / 9期

关键词：

Endoscopic anti-reflux therapy (EART); Endoscopy; Gastroesophageal reflux disease (GERD); Laparoscopy; Minimally invasive solutions; Proton pump inhibitor;

D O I：

10.1007/s11894-016-0521-1

中图分类号：

学科分类号：

摘要：

Early in the twenty-first century, novel endoscopic techniques were introduced for the management of gastroesophageal reflux disease, providing minimally invasive ways to eliminate pharmacologic acid inhibition and avoid the need for anti-reflux surgery. These techniques do not significantly alter the anatomy of the gastroesophageal junction, minimizing short- and long-term adverse effects, such as dysphagia and bloating. After extensive clinical testing, many endoscopic therapies were abandoned due to either lack of durable efficacy or unfavorable safety profile. Today, only four such therapies remain clinically available, each with variable levels of clinical validation and market penetration. This review will provide an assessment of these endoscopic therapies, highlighting their respective strengths and weaknesses and their present and future applicability to patients with gastroesophageal reflux disease. © 2016, Springer Science+Business Media New York.

引用

共 42 条

[1]

Subramanian C.R., Triadafilopoulos G., Refractory gastroesophageal reflux disease, Gastroenterol Rep (Oxf), 3, 1, pp. 41-53, (2015)

[2]

Kamolz T., Pointner R., Expectations of patients with gastroesophageal reflux disease for the outcome of laparoscopic antireflux surgery, Surg Laparosc Endosc Percutan Tech, 12, 6, pp. 389-392, (2002)

[3]

Reimer C., Safety of long-term PPI therapy, Best Pract Res Clin Gastroenterol, 27, 3, pp. 443-454, (2013)

[4]

Hirano I., Richter J.E., Practice Parameters Committee of American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing, Am J Gastroenterol, 102, pp. 668-685, (2007)

[5]

Yuan Y., Hunt R.H., Evolving issues in the management of reflux disease?, Curr Opin Gastroenterol, 25, 4, pp. 342-351, (2009)

[6]

Frazzoni M., Manno M., De Micheli E., Savarino V., Efficacy in intra-oesophageal acid suppression may decrease after 2-year continuous treatment with proton pump inhibitors, Dig Liver Dis, 39, 5, pp. 415-421, (2007)

[7]

Lin D., Triadafilopoulos G. Dual ambulatory ph monitoring in patients with gastroesophageal reflux rendered asymptomatic with proton pump inhibitor therapy, Dig Dis Sci, 60, 5, pp. 1343-1349, (2015)

[8]

Galindo G., Vassalle J., Marcus S.N., Triadafilopoulos G., Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy, Dis Esophagus, 26, 5, pp. 443-450, (2013)

[9]

Frazzoni M., Piccoli M., Conigliaro R., Frazzoni L., Melotti G., Laparoscopic fundoplication for gastroesophageal reflux disease, World J Gastroenterol, 20, 39, pp. 14272-14279, (2014)

[10]

Roman S., Lin Z., Kwiatek M.A., Et al., Weak peristalsis in esophageal pressure topography: classification and association with dysphagia, Am J Gastroenterol, 106, pp. 349-356, (2011)

← 1 2 3 4 5 →